Press "Enter" to skip to content

CVS Stops Selling Zantac for Possible Risk of Cancer

CVS has announced it’s no longer selling widespread heartburn drugs Zantac or its generic version because of the possible link to cancer investigated by the U.S. Food and Drug Administration. On Saturday, CVS Health Corp announced it might cease selling the over-the-counter heartburn medicines “out of an abundance of warning.” CVS says it’s not recommending people stop taking the medication; however, it’s encouraging customers who purchased any of these products can return them for a refund.

In massive quantities, the FDA says chemicals discovered in the products are believed to trigger cancer; however, the amount present in Zantac isn’t rather more than what could be found in regular foods.

CVS says it’s going to proceed to sell different heartburn medicines like Pepcid and Tagamet along with their generic equivalents. Zantac is sold by Sanofi which is reportedly cooperating with the FDA in addition to conducting its investigations.

Sandoz, a unit of Switzerland-based pharmaceutical giant Novartis, halted the distribution of generic versions earlier this month.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *